DNA Mutation Detection in Circulating Tumor DNA and Tissue by mmADPS for Pancreatic Cancer

DNA Mutation Detection in Circulating Tumor DNA and Tissue by Massive Multiplex Allele Discrimination Priming System(mmADPS) for Pancreatic Cancer

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05604573

Enrollment

150

Registered

2022-11-03

Start date

2022-02-09

Completion date

2024-12-31

Last updated

2022-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer

Keywords

Pancreatic cancer, Circulating Tumor DNA, DNA mutation, DNA methylation

Brief summary

Based on the cell free nucleic acid analysis information of blood samples and genetic mutation profile of EUS-FNB tissue from pancreatic cancer, the concordance between them is evaluated. And based on this information, biomarkers for diagnosis, treatment, and prognosis of pancreatic cancer are explored.

Interventions

DIAGNOSTIC_TESTcell free DNA in blood, genetic mutation in tissue

Diagnostic test for cell free DNA in blood, genetic mutation in tissue

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Patients diagnosed with pancreatic cancer through histological or radiologic examination and before treatment begins * Patients aged 18 or older who voluntarily agrees to participate in the study and is willing to understand and comply with the subsequent treatment procedures and sample collection schedule * Among patients diagnosed with benign pancreatic diseases (pancreatic cyst, chronic pancreatitis, etc.), patients who have need for histological examination as control group

Exclusion criteria

* Where the subject himself/herself refuses to fill out the consent form or is unable to fill out the consent form * If a laboratory test is impossible due to a qualitative problem with the collected blood sample * Where the collected tissue does not contain tissue of the desired malignant or benign disease

Design outcomes

Primary

Measure	Time frame	Description
correlation of genetic mutation	the day of study enrollment (baseline)	concordance of genetic mutation between tissue and blood of treatment-naive status
detection sensitivity of genetic mutation by mmADPS	the day of study enrollment (baseline)	detection sensitivity of genetic mutation by mmADPS

Secondary

Measure	Time frame	Description
correlation of genetic mutation and prognosis	through study completion, an average of 1 year	correlation of genetic mutation and prognosis

Countries

South Korea

Contacts

Primary ContactSang Hyub Lee, Ph.D

gidoctor@snu.ac.kr+82-2-2072-2228

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026